Fundamental Analysis of EXSCIENTIA PLC(NASDAQ:EXAI) stock

Fundamental Rating

EXAI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While EXAI seems to be doing ok healthwise, there are quite some concerns on its profitability. EXAI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EXAI has reported negative net income.

In the past year EXAI has reported a negative cash flow from operations.

EXAI had negative earnings in each of the past 5 years.

In the past 5 years EXAI reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -31.93%, EXAI is in the better half of the industry, outperforming 70.21% of the companies in the same industry.

The Return On Equity of EXAI (-45.85%) is better than 70.38% of its industry peers.

		Industry Rank	Sector Rank
ROA	-31.93%
ROE	-45.85%
ROIC	N/A

ROA(3y)-18.33%

ROA(5y)-19.31%

ROE(3y)-25.04%

ROE(5y)-27.69%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EXAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EXAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for EXAI has been increased compared to 1 year ago.

EXAI has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.11, we must say that EXAI is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of EXAI (1.11) is better than 67.29% of its industry peers.

A Debt/Equity ratio of 0.05 indicates that EXAI is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.05, EXAI is doing worse than 60.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	1.11

ROIC/WACCN/A

WACC8.31%

2.3 Liquidity

A Current Ratio of 6.22 indicates that EXAI has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 6.22, EXAI is in the better half of the industry, outperforming 63.53% of the companies in the same industry.

EXAI has a Quick Ratio of 6.22. This indicates that EXAI is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 6.22, EXAI is doing good in the industry, outperforming 63.87% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.22
Quick Ratio	6.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EXAI have decreased by 0.00% in the last year.

Looking at the last year, EXAI shows a very negative growth in Revenue. The Revenue has decreased by -34.54% in the last year.

The Revenue has been growing by 17.43% on average over the past years. This is quite good.

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-10.53%

Revenue 1Y (TTM)-34.54%

Revenue growth 3Y17.43%

Revenue growth 5YN/A

Revenue growth Q2Q-69.59%

3.2 Future

The Earnings Per Share is expected to grow by 4.53% on average over the next years.

The Revenue is expected to decrease by -10.40% on average over the next years. This is quite bad

EPS Next Y0.16%

EPS Next 2Y-1.65%

EPS Next 3Y4.53%

EPS Next 5YN/A

Revenue Next Year89.84%

Revenue Next 2Y-0.15%

Revenue Next 3Y-10.4%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAI. In the last year negative earnings were reported.

Also next year EXAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.65%

EPS Next 3Y4.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EXAI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EXSCIENTIA PLC

NASDAQ:EXAI (4/26/2024, 7:00:02 PM)

4.03

+0.04 (+1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap508.26M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.93%
ROE	-45.85%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.22
Quick Ratio	6.22
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y0.16%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-34.54%

Revenue growth 3Y17.43%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EXSCIENTIA PLC (EXAI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens